Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Univec (UNVC) -- Ignore unavailable to you. Want to Upgrade?

To: r. peter Dale who wrote (77)	11/6/1997 1:58:00 AM
From: Courtney Willfore	Read Replies (1) \| Respond to of 181

Pete - Sorry, I did see your post earlier but had to run (literally). I'm familiar with the caspases but you've shed a whole new light on them. PubMed has over 100 refs so I'll be doing some legwork. Do you think the caspases can be targeted like Ariad is approaching small molecule drug design for SHXs and STATS? I wonder if going after the caspases may be intervening at a stage too proximal to the grim reaper. The abstract from the paper you cited suggested not but.... What about modulating macrophage effectors in an attempt to abrogate the start of death signaling processes. Modulate cyclooxygenase-2, inducible nitric oxide synthase, superoxide dismutase ++ so to reduce reactive compounds in the brain. I know this is too broad..I'll work on it. Thanks Peter, you're a wonderful resource. Courtney